Aia Tokyo Intnationa Conn 2020

Accelerate your Pathway to Partnerships in Asia MARCH 10-11, 2020 • TOKYO, JAPAN

General Overview • Advisory Committee • Education and Conference Programming •

Partnering • Sponsorship Opportunities •

#BIOASIA20 • bio.org/asia The BIO Asia International Conference is an exclusive partnering forum that brings together the global biotechnology and pharmaceutical industry to explore licensing and investor engagement in the current Asia-Pacific business and policy environments.

Event Attributes and Opportunities

• Gain insights into the changes, challenges, and opportunities collaborations and funding opportunities with participating key opinion and policy leaders foresee for the Japanese companies; communicate directly with conference attendees; biotech market. and pre-schedule private, 30 minute One-on-One meetings to be conducted onsite. • Facilitate connections with strategic partners looking to invest, partner, or license in or license out, early to late-stage • Panel discussions will increase your understanding of, programs in your therapeutic area of focus. and interaction with, the Japanese biotech market, the political landscape in Japan, and its impact on this important Opportunity for organizations to deliver company • industry sector. presentations, providing increased visibility in front of a global audience of biotech and pharmaceutical companies, all • Network with government leaders, peers, investors, and interested in cross-border business development alliances and potential partners attending the conference and our exclusive research collaborations. welcome reception. • BIO One-on-One Partnering enables attendees to search • Exclusive sponsorship opportunities to showcase thought company and investor profiles, drug assets, products, leadership, elevate brand identity and maximize partnering and services in the biopharma industry; evaluate potential benefits with an elite audience.

ATTENDANCE BY REGION WHO SHOULD ATTEND: • Drug development and discovery companies • Biopharmaceutical companies Asia 50% • Medical technology companies Europe 15%Other 4% • Universities and institutes North America 31% • Intellectual property and legal organizations • Investors and financial services providers • Bio-clusters and incubators • Government and public support agencies

HIGHLIGHTS / STATISTICS FROM PRIOR YEAR

400+ 27 250+ 1,270+ 50 DELEGATES COUNTRIES COMPANIES BIO ONE-ON-ONE INNOVATIVE COMPANIES REPRESENTED PARTNERING MEETINGS FROM AROUND THE WORLD PRESENTING THEIR STORY

CE NVESTOR 1 CO-HOSTED BY:#BIOASIA20 • bio.or® g/asia CONFERENCE 2019 Advisory Committee Each year, BIO assembles a group of industry thought leaders to help us shape the conference program and provide input on key topics and themes that deliver excellence for all attendees.

HENRY CHEN, JD RYO KUBOTA, MD, PHD TED TANAKA Managing Partner, Delos Capital Representative Executive Partnering Consultant, Tanaka Officer, Chairman, President and International LLC Chief Executive Officer, Kubota Pharmaceutical Holdings Co., Ltd.

PATRICK FLOCHEL BO LIU, PHD GIL VAN BOKKELEN, PHD Global Life Sciences Sector Principal, Venture Investments, Chairman and Chief Executive Leadership Team, Tokyo, Johnson & Johnson Development Officer, Athersys Ernst & Young Corporation – JJDC, Inc. (JJDC)

KYLE HATHAWAY, PHD ARLENE MORRIS DAMIEN VILLENEUVE Director of Policy and Government Chief Executive Officer, Vice President, Business Relations, Asia Pacific, MSD, Merck Willow Advisors Development Asia-Pacific and Japan, Lupin

APO HUANG, PHD KYLE MURPHY HAYATO WATANABE Secretary General, Taiwan Bio Managing Director and Founder, Vice President, Tokyo, Industry Organization KMG Japan Locust Walk

TARO INABA TORU SEO, PHD DALE YAKIN Managing Partner, Remiges Senior Director, Head, External Managing Director, VelocityHealth Ventures R&D Innovation Japan, Worldwide Securities Research & Development, Pfizer, Inc.

YUICHI IWAKI, MD, PHD BT SLINGSBY, MD, PHD, MPH TAKAFUMI YAMAMOTO President and Chief Executive CEO & Executive Director, Global Chief Executive Officer and Officer, MediciNova Health Innovative Technology President, TODAI TLO (GHIT) Fund

AMY JACKSON CHARLES STACEY, MD Japan Representative, PhRMA Chief Executive Officer, Cerecin Apply to join the 2020 Committee by emailing your interest to [email protected] SHINICHIRO KOMOTO RAMI SUZUKI, PHD Partner, Eight Roads Senior Director, Head of Japan Business Development, The Janssen Pharmaceutical Companies, Johnson & Johnson

CE NVESTOR 2 #BIOASIA20 • bio.org/asia CONFERENCE Education and Conference Programming General themes at the BIO Asia International Conference focus on deal-making trends in the Japanese market, adapting clinical trial strategies across regulatory regimes, and shifts in Asian investment patterns among different therapeutic development specialties.

2019 BIO ASIA CONFERENCE RECAP How is the Drug Pricing Reform Initiative Affecting Explaining CFIUS and New Investment Regulations Patient Access, Investment, and Innovation in the United States in Japan? Market participants were updated on the evolving national security The Japanese government is pursuing a series of policy reforms review process and its impact on the biotechnology industry, as well that affect the pricing of medicines involving new cost-effectiveness as how additional rules may impact future business development frameworks and other reimbursement guidelines that poorly align and investment opportunities. with the value of biotechnology innovations, many of which are already treating patients successfully in other countries. Biotech Incubator Business Models: Lessons and Needed Improvements Reshaping Tumor Microenvironments Corporate biopharmas have decades of experience with university via Immunotherapies collaborations and open incubator models that produce research The panelists discussed the next wave of innovation in and pre-clinical data, but disappointingly few new medicines. What immunotherapies—how tumor microenvironments develop to features of incubators create value and where should incubator create treatments able to demonstrate more durable effects on business model innovation go next? This panel will consider lessons shrinking tumors across wider ranges of patients. learned from different sized organizations in different geographies and therapeutic areas that have attempted to improve R&D with Turning RNA Interference Research into Medicines external collaborators. The approval of the first siRNA-based therapeutic this year has Using M&A for Data Advantages Beyond opened the door for companies to pursue expansion of this class of medicines. Deal activity, the progress of academics, and a favorable Product Pipelines regulatory environment in Japan have contributed to interest in the Takayuki Ooka, Partner, Valuation, Modeling & Economics, Ernst & field. The discussion included updates on current approaches and Young Transaction Advisory Services Co. led a conversation about techniques for this pipeline of therapeutics. domestic and international biopharma deal trends, pinpointing regional opportunities to specialize or build value though digitizing Bridging External Innovation and Internal R&D for R&D workflow. New Patient Therapies Strategic cross-border application of licensing agreements accelerates the path of an idea for a new medicine to get from the research laboratory to the patient needing treatment.

CE NVESTOR 3 #BIOASIA20 • bio.org/asia CONFERENCE REPRESENTATIVE PROGRAM SPEAKERS Jun Bao, PhD Lindi Tan, PhD President and Chief Executive Officer Chief Financial Officer Impact Therapeutics Ascletis Pharma Inc. Michael Chan Masako Nakamura Head of International Issuer Business Head of Asia Hong Kong Exchanges and Clearing Limited (HKEX) Alnylam Pharmaceuticals President and Representative Director Niels Emmerich, PhD Alnylam Japan K.K. Vice President Global Head Search & Evaluation, AbbVie Gil Van Bokkelen, PhD Chairman and CEO Lei Gao, PhD Athersys Executive VP/Deputy GM Harbin Pharmaceutical Group Co., Ltd. Michael Wang, PhD Vice President China BD and Alliance Management Pingsheng Hu, PhD Brii Biosciences President and Chief Executive Officer Sinorda Biomedicine Ltd. Hayato Watanabe Partner Hardy TS Kagimoto, MD Locust Walk Chairman and CEO Healios K.K.

Company Presentations The BIO Asia International Conference assembles U.S. and European drug development companies, as well as Asian biotech and pharmaceutical companies interested in research collaborations and licensing agreements. Presenting companies at the event are biopharmas ready to engage in cross-border partnerships and licensing discussions.

Philanthropy 2%

Multiple Discovery Products Other/Not Applicable 7% in Market 17% 5% Publicly Traded Company Pre-Clinical 21% 26% Development Types of Phase of Presenting Presenting Phase III 12% Companies Companies

Phase II 12% Phase I Privately Funded Company 21% 74%

CE NVESTOR 4 #BIOASIA20 • bio.org/asia CONFERENCE Partnering BIO One-on-One Partnering is the most efficient way to do business in the biotech and pharma industry without traveling all over the world. Our system makes it easy to search for and identify potential partners and request meetings with prospective biotech investors and senior business development executives.

Musculoskeletal disorder 2% Ocular disease 2% Metabolic disorder 3% Genitourinary disease 3% Endocrine disease 4% Neoplasm Other CEO-level 11% 25% 20% Inflammatory disease 4% Neurological disease Primary 11% Seniority Level Other C-suite Respiratory disease 5% 10% Therapeutic Areas of Attendees Gastrointestinal By Scheduled Meetings disease Immune disorder 5% 7%

BD DIRECTOR-LEVEL Cardiovascular VP-level disease 26% 19% Gynecology and obstetrics 5% Infectious 7% disease 7%

Hermatological disease 6% Dermatological disease 6% 2019 PARTICIPATING COMPANIES 3Z Brandenburg Invest Golden Biotechnology Corp. Merck Socium A. Menarini IFR Bridge Biotherapeutics Government of Alberta Japan Merck Life Science/BioReliance SOUSEIKAI Global Clinical Ab Studio Brii Biosciences Office End-to-End Solutions Research Center AbbVie Business France Japan Green Cross Corporation (GC MinervaX Southern Star Research Pty Abcuro CanBas Pharma) Ministry of Science and Technology SPA Les Laboratoires Frater-Razes Accelerated Biosciences Corp. Can-Fite BioPharma HanaVax Mirati Therapeutics Spectrum Pharmaceuticals Acorda Therapeutics Caprion Biosciences Hangzhou Sinorda Pharmaceutical MSD K.K. Standigm ACT Genomics Casebia Therapeutics Harbin Pharma Nationl Center for Globale Health Stelexis Therapeutics Aduro Asia Cellerant Therapeutics Hua Medicine and Medicine Suda pharmaceuticals AfricaBio CELLSEED Huons Co. NB Health Laboratory Co. Summit Pharmaceuticals AIMM Therapeutics BV Cerecin iHeart Japan Corporation NeuroVive Pharmaceutical International Corp. Aivita Biomedical ChemRar RDI I-Mab Biopharma Newcastle University SunRock Biopharma Ajinomoto Chitose Biologics Immune Design NEXEL Co. Suntec Medical (Taiwan) AlivaMab Discovery Services & Cidara Therapeutics Impact Therapeutics Nitto Boseki SUSMED Ablexis Cipla Indena SpA Omicsway Synthetic Biologics Alnylam Pharmaceuticals City of Sapporo Industrial Technology Research Oncolys BioPharma TAGCyx Biotechnologies AMAG Pharmaceuticals CK Biotech Institute Onconova Therapeutics Taisho Pharma American BriVision (Holding) Clarivate Analytics Informa OniX Hub & Ventures Taiwan Bio Industry Organization Corporation Copenhagen Capacity Innovation Center/CJ HealthCare Optimata Takeda / Gene Therapy Center Amgen Covance Japan Insilico Taiwan Panacea Venture Austria (GTCA) AMRA Medical Crux Health Technologies InveniAI Pfizer Takeda Pharmaceutical Company AnaBios CSL Behring K.K. Invest in Bogota Pfizer Japan/ Corporate Affairs, Tanaka International Anima Biotech Daewoong Pharmaceutical IRBM SpA Health & Value, New Asset & Tasly Pharmaceutical Group Aquilo Partners Daiichi Sankyo Co. Isofol Medical AB (publ) Access Strategy Group Taylor Construction Management Ascent Therapeutics Daré Bioscience Japan Bioindustry Association Pharmaceutical Research and Teikoku Seiyaku Co. Ascletis Pharma Deerfield Management Jemincare Therapeutics Corp Manufacturers of America The Hong Kong University of AsiaBioNext Pte Delta-Fly Pharma Jiangsu Atom Bioscience and Pierre Fabre Medicament Science and Technology ASLAN Pharmaceuticals Development Center for Pharmaceutical Poxel SA TNO Aspect Biosystems Biotechnology JSR Corporation Precision Nanosystems TOA EIYO AstraZeneca Donnelley Financial Solutions JT Pharma Proteina Co. TODAI TLO Athersys DyDo Pharma Juvabis AG QIMR Berghofer Tokyo Medical and Dental AUM Biosciences EditForce KAC Co. ReForm Biologics University Aurora Partners K.K. Eight Roads Ventures Kaken Pharmaceutical Rin Institute Toray Industries Avilex Pharma Eli Lilly and Company Kaunas University of Technology Rockwell Medical Trianni BaselArea.swiss Embassy of Italy KinoPharma Salzman Group twoXAR Bayer Yakuhin Embassy of the Federal Republic of Kitov Pharma Samsung BioLogics U.S. Chamber of Commerce Bayer Germany Kleo Pharmaceuticals Sanofi Pasteur UCB Japan Co. Beigene Switzerland GmbH Endoceutics KMG Japan Sansho University of Arizona Beijing Taiyangsheng High-Tech EphyX Neuroscience Kolon Life Science Santen Pharmaceutical VelocityHealth Pharmaceutical EpiVax Kyowa Hakko Kirin Scohia Pharm VORONOI Berlin Partner for Business and Ernst & Young LegoChem Biosciences Secretariat of BioJapan/ W Global Capital Limited Technology Evec Life Biosciences Regenerative Medicine Japan Whanin Pharm BioCentury FIMECS Life Science Innovation Network SEEDSUPPLY Willow Advisors BioInspira Flanders Investment & Trade Japan (LINK-J) SENAGRO-BUSINESS Xcovery Holdings BioInvent International AB Fuji Yakuhin Locust Walk Sensile Medical AG Y-Biologics Biomere Tech G M ENTERPRISES M Bio Technology Servier YD Life Science bioskin GmbH GE Healthcare Machavert Pharmaceuticals Shaperon YUMAB GmbH BioXcel Therapeutics Genesis Healthcare K.K. MacroGenics Shenzhen Sanofi Pasteur Biological Zai Lab Blirt Genmab McDonnell Boehnen Hulbert & Products Boehringer Ingelheim Japan GEXVal Berghoff Sidley Boston Pharmaceuticals Global Health Innovative MDNA Life Sciences SM Investment Group BPN Life Science Technology Fund Medbanks Group SM-Sino Technology Investment CE NVESTOR 5 #BIOASIA20 • bio.org/asia CONFERENCE 2020 Sponsorship Opportunities

Recognition Partnering on Conference Suite and Website, Advertisement Acces to BIO Priority Guaranteed Number of Materials and in Conference One-on-One Scheduling Speaking Registrations Signage Program Partnering* of Meetings Opportunity Showcase Thought Leadership Program Sponsor 3      Company Presentations Sponsor 2   

Access Your Target Audience Welcome Reception Sponsor 2    Hospitality Sponsor 1    Executive Roundtable Dinner Tabletop Exhibit Sponsor 1 

Maximize Partnering & Deal Making

BIO One-on-One Partnering 2     System Sponsor Partnering Suite Package 2    

Boost Brand Visibility Lanyard Sponsor 1    Conference Program Sponsor 1    WiFi Sponsor 1    Attendee Gift Sponsor 1   High Visiblity Onsite Branding Conference Program Advertisement 

*US/EU headquartered service providers do not receive access to the BIO One-on-One Partnering system through attendee registration. To gain access to the Partnering system, consider sponsoring these opportunities.

• Our Sales & Sponsorship team is always CONFERENCE VENUE AND HOTEL ready to support your cross-Pacific event GRAND HYATT TOKYO goals. Please feel free to reach out to the 6-10-3 Roppongi Minato-Ku, Tokyo, Japan, 106-0032 Bio has reserved a block of hotel rooms team at +1.202.312.9264 or sponsor@bio. for the 2020 BIO Asia Conference. CE NVESTOR 6 #BIOASIA20 • bio.org/asia CONFERENCE